Q&A With Alasdair Coles of Cambridge Neurology: Alemtuzumab As Aggressive Multiple Sclerosis Treatment

For as many drugs and therapies as there are for multiple sclerosis some are more aggressive than others. Alemtuzumab's approach is more on the aggressive end of the spectrum.

Alasdair Coles from Cambridge Neuroscience discussed the medication during the American Academy of Neurology's annual meeting in Washington DC. One of the key features of the medication is its delivery which includes an intensive start and trails off to allow patients to go several years without needing any additional medication. With such strong treatment there is also a risk of adverse events which Coles also talked about.